ArticlemedRxiv : the preprint server for health sciences2025
HIV status is not associated with SARS-CoV-2 viral load and longer duration of infection among people with well-controlled HIV and high COVID-19 vaccine coverage.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
backgroundHIV may alter SARS-CoV-2 viral load and increase the duration of SARS-CoV-2 infection and, thereby, drive the emergence of variants of concern. This study investigated the association between HIV with SARS-CoV-2 viral load and duration of infection in Botswana, in the era of high antiretroviral therapy (ART) coverage.
methodsThis cohort study was conducted in Gaborone, Botswana, covering 6 healthcare facilities. Gaborone residents with confirmed SARS-CoV-2 infection were recruited through active screening, passive diagnosis, and contact tracing. Among enrolled participants, we conducted weekly serial testing for SARS-CoV2. The primary outcomes for this analysis were SARS-CoV-2 viral load and duration of SARS-CoV-2 infection. SARS-CoV-2 viral load was measured using RT-PCR cycle threshold (Ct) value at the time of diagnosis with higher Ct value indicating a lower viral load. Duration of SARS-CoV-2 infection was calculated as the number of days between symptom onset and date of negative PCR test. Multiple linear regression and Cox-proportional hazard models were employed to determine the association between HIV infection status and outcome variables.
findingsOf the 578 enrolled participants, 486 (84.1%) with known HIV status were included in the analysis. Of the population, 69.3% were female, mean age was 37.8 years, and 88.7% were vaccinated for COVID-19. People living with HIV (PLWH) accounted for 26.1% of the population, with a mean CD4+ T cell count of 715 cells/μL. Among PLWH, 86.6% were taking ARTs at the time of diagnosis. The mean Ct value across all participants was 22.5 (SD: 6.16). No significant difference in Ct values was observed between HIV and CD4+ T cell categories. A significant association was found between age and Ct values (β = -0.05, 95% CI: -0.11, 0.00, p = 0.03). Survival analysis showed increased time to negative COVID-19 PCR for PLWH with CD4+ T cell count ≥ 500 cells/μL (HR = 1.45, 95% CI: 1.02, 2.05, p = 0.03) compared to people without HIV, but not for PLWH CD4+ T cell count < 500 cells/μL (HR = 1.01, 95% CI: 0.62, 1.65, p = 0.9).
interpretationAmong PLWH with well-controlled HIV disease and high vaccine coverage, we found no evidence of an association between HIV status with SARS-CoV-2 viral load or increased duration of SARS-CoV-2 infection. Additional research is needed to confirm shorter duration of SARS-CoV-2 infection among PLWH with CD4+ T cell counts ≥ 500 cells/μL. SOURCE OF
fundingThis research was supported by US NIH grant #R01AI170204.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.